Definition, Pathogenesis, and Management of That Cursed Dyspepsia

Similar documents
Number of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI

Functional Dyspepsia

Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments

Functional Heartburn and Dyspepsia

Management of Functional Dyspepsia (FD)

CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University

Non-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics

June By: Reza Gholami

6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures

The Role of Food in the Functional Gastrointestinal Disorders

Grigoris Leontiadis, MD PhD. McMaster University Upper Gastrointestinal and Pancreatic Diseases Cochrane Group

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

SUPPLEMENTARY INFORMATION Associated with

Functional Dyspepsia. Norbert Welkovics Heine van der Walt

Dyspepsia is a problem commonly seen by primary

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA

New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome

Chapter 1. General introduction and outline

GASTROPARESIS. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis

JNM Journal of Neurogastroenterology and Motility

Real World Efficacy and Tolerability of Acotiamide in Relieving Multiple and Overlapping Symptoms in Patients of Functional Dyspepsia

An approach to dyspepsia for the pharmacist

Our evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders.

REVIEW ARTICLE: ENDPOINTS USED IN FUNCTIONAL DYSPEPSIA DRUG THERAPY TRIALS

From Department of Medicine, Huddinge, Division of Gastroenterology and Hepatology Karolinska Institutet, Stockholm, Sweden

Gut involvement in PoTS an overview

Rumination Definition

QUICK QUERIES. Topical Questions, Sound Answers

Does the Injection of Botulinum Toxin Improve Symptoms in Patients With Gastroparesis?

Objectives. Identify age-related changes in the gastrointestinal tract

HELICOBACTER PYLORI; PATIENTS WITH FUNCTIONAL DYSPEPSIA

F unctional gastrointestinal disorders (FGID) are clinical

Title. CitationDigestion, 87(1): Issue Date Doc URL. Rights. Type. File Information. Novel Drinking-Ultrasonography Test

Gut complications in autonomic dysfunction Qasim Aziz, PhD, FRCP

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013

Reflux of gastric contents, particularly acid, into the esophagus

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Dyspepsia: alarm symptoms, investigation and management

Corporate Medical Policy

Classification of pediatric functional gastrointestinal disorders related to abdominal pain using Rome III vs. Rome IV criterions

ESOPHAGEAL MOTOR DISORDERS

Amyloidosis & the GI Tract

GI Health Foundation DDW 2016 Functional Dyspepsia: A New Disease Model. Nicholas J. Talley MD, PhD

Dyspepsia and upper gastrointestinal bleeding. Dr. Wayne H.C. Hu 胡興正

Is a field of radiology that uses unsealed radiation for diagnostic or therapeutic reasons Is a method of physiologic imaging, very different than

Functional Dyspepsia

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

FUNCTIONAL DISORDERS ROME IV CRITERIA AND DIAGNOSTIC QUESTIONNAIRE DDW 2016,REVIEW. Presented by; Marjan Mokhtare Gastroenterologist, IUMS

Final published version:

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

GI Complications in heds and HSD

IBS - Definition. Chronic functional disorder of GI generally characterized by:

Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence

J Neurogastroenterol Motil, Vol. 17 No. 3 July, 2011 DOI: /jnm Journal of Neurogastroenterology and Motility

Gastroesophageal Reflux Disease, Paraesophageal Hernias &

PELVIC PAIN : Gastroenterological Conditions

Theme: Gastric Dyspepsia. Chronic gastritis and duodenitis.

Prevalence of dyspepsia: the epidemiology of overlapping

Functional dyspepsia: recent advances in pathophysiology. Citation Hong Kong Practitioner, 1998, v. 20 n. 6, p

Clinical Evaluation of Himcocid Suspension in Patients with Non-ulcer Dyspepsia

GASTRIC EMPTYING STUDY (SOLID)

An Approach to Abdominal Pain

What you really need to know about Gastroparesis?

Subgroups of Dyspepsia

A Trip Through the GI Tract: Common GI Diseases and Complaints. Jennifer Curtis, MD

HOW TO NATURALLY TREAT INDIGESTION YOGI CAMERON

Diarrhea may be: Acute (short-term, usually lasting several days), which is usually related to bacterial or viral infections.

A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori- Negative Primary Care Patients with Dyspepsia in Japan

The Aging Digestive System

IBS: overview and assessment of pain outcomes and implications for inclusion criteria

Geographical and Cultural Food-related Symptoms, Food Avoidance and Elimination

Management of dyspepsia and of Helicobacter pylori infection

MANAGEMENT OF DYSPEPSIA

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Dyspepsia and Chronic Gastritis

Microbiome GI Disorders

Setting The setting was primary care. The economic study was conducted in Canada.

Copy right protected Page 1

A PLACEBO CONTROLLED TRIAL OF BISMUTH SALICYLATE IN HELICOBACTER PYLORI ASSOCIATED GASTRITIS

Gastroparesis and other upper GI problems DR ANDREW DAVIES

Gastroparesis. - Recent advances in the pathophysiology and treatment -

Module 2 Heartburn Glossary

Clinical Policy Title: Noninvasive testing for H. pylori

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

Clinical Policy Title: Noninvasive testing for H. pylori

LINX. A new, FDA approved treatment for GERD

A Community-Based, Controlled Study of the Epidemiology and Pathophysiology of Dyspepsia

DYSPEPSIA Dyspepsia indigestion during or after eating Full Heat, burning or pain Note: one of every four people

Motility Conference Ghrelin

When to Refer for OGD and the Work Up of Upper GI Malignancies

Dyspepsia is a constellation of symptoms referable to the gastroduodenal

IBS. Patient INFO. A Guide to Irritable Bowel Syndrome

JMSCR Vol 06 Issue 09 Page September 2018

Objectives. Pain Types Brief Review. Referred Pain. Chronic/Recurrent Abdominal Pain 1/12/2017. I have no conflicts of interest to disclose

Managing Upper GI Tract Disease. Michael Herzlinger, MD Pediatric Gastroenterology 7/2018

Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia

GASTRO-OESOPHAGEAL REFLUX DR RONALDA DELACY

Transcription:

Clinical Gastroenterology and Hepatology 2018;16:467 479 Definition, Pathogenesis, and Management of That Cursed Dyspepsia Pramoda Koduru, Malcolm Irani, and Eamonn M. M. Quigley IM F1 김영기

Dyspepsia Umbrella term to refer number of nonspecific symptoms originate from UGI Minority: potentially life threatening Majority: functional Difficult to definition and manage functional dyspepsia (FD) Crean et al (1994), Dyspepsia is episodic recurrent or persist ent abdominal pain or discomfort, or any other symptoms refe rable to the upper alimentary tract, excluding bleeding or jaun dice, of duration 4 weeks or longer, including abdominal pain/ discomfort, heartburn or other manifestations of gastroesopha geal reflux, anorexia, nausea and vomiting, flatulence or air er uctation (belching, burping or aerophagy), early satiety or und ue repletion after meals, abdominal distension or bloating Overlap? GERD, IBS

Functional dyspepsia (FD) Functional = nonstructural or non-organic No gold standard for the definition of FD Diagnosis of exclusion after exclusion of all organic causes Geographic variation: related in large part to H.pylori prevalence Problem of misunderstanding on the very symptoms of sufferer Physician bias: less commonly used in the US, where FD-type symptoms are designated as GERD. Rome I (1989-1994) and II (1999): Any symptoms - Reflux type, ulcer type, dysmotility type, unspecified Rome III (2006) and IV (2016): More specific - Post-prandial distress syndrome (PDS): meal-induced dyspeptic symptoms; bothersome postprandial fullness; early satiety (+epigastric pain or burning that worsens with meals, on Rome IV) for 3 d/wk; - Epigastric pain syndrome (EPS): occurred in between meals; epigastric pain and/or burning for 1 d/wk.

FD: Rome III (2006) Excluded prominent heartburn or satisfied criteria for IBS Despite the fundamental change, sensitivity or specificity to identify FD was not different from previous criteria

FD: Rome IV (2016) FD should no longer be considered as a single disease entity but rather as a spectrum where there is significant overlap with GERD and IBS. Bothersome; occur more frequently than normal population

Epidemiology of FD Prevalence: 10~30% (problem of definition) Global pooled prevalence: 21% Higher in: women, smokers, NSAID users, H. pylori-positive pts. Western (ulcer-like, reflux-like) > Eastern (dysmotility like) SES tends to low in western, while high in Eastern. H. pylori eradication is more effective for Sx in Eastern. Higher economic impact in Western.

Pathophysiology of FD

Pathophysiology of FD Delayed gastric emptying Traditionally, thought to be one of the main players. 20~50% among dyspepsia sufferers 1.5 times slower on gastric emptying of solid than control subjects Symptom overlap between PDS and idiopathic gastroparesis Post-prandial fullness: related with delayed gastric emptying vs. other symptoms: not related with delayed gastric emptying Paradoxically rapid gastric emptying in small population

Pathophysiology of FD Impaired accommodation Ingestion vasovagal reflex nitrergic nerve fundus & HB relax Antrofundic reflex 40% in FD Early satiety: related with Barostat: gold standard, but invasive Drink challenge test: lower volume in FD US, SPECT, MRI Hypersensitivity Barostat 34% in FD Postprandial epigastric pain, bel ching, weight loss

Pathophysiology of FD Duodenal hypersensitivity to acid and lipid 59% of FD developed nausea during a brief period of duodenal acid perfusion reduced clearance of exogenously administered acid from the duodenal bulb Directly via duodenal receptors and sensory nerves or indirectly through feed back changes in proximal gastric function intraduodenal infusion of lipids sensitized the stomach to distention and prov oked symptoms of fullness, discomfort, and nausea

Pathophysiology of FD Postinfectious De novo development of FD following an enteric infection Early satiety, nausea, weight loss; symptoms were attributed to impaired acco mmodation resulting from dysfunction of gastric nitrergic neurons. Salmonella enteritis: the relative risk for the development of FD was 5.2 Giardia lamblia infection has been shown to provoke visceral hypersensitivity and delay gastric emptying

Pathophysiology of FD Inflammation PI-FD: CD8+, CD4+, MΦ in duodenum Not confined to PI-FD, mast cell in FD EC cells in PI-FD Augmented expression of histamine, seroto nin, and tryptase in gastric mucosal biopsy samples in FD Systemic inflammation

Pathophysiology of FD Duodenal eosinophilia (not gastric) OR for the FD in subjects with high duodenal bulb Eo counts was 11.7 Early satiety, postprandial fullness: 2 nd portion Abdominal pain: bulb & 2 nd portion Related with PDS and allergy

Pathophysiology of FD H. pylori infection via a variety of disturbances in acid secretion, motility, and neuroendocri ne signaling may influence gastric hypersensitivity (effect of inflammation)

Pathophysiology of FD Psychosocial: stress, anxiety, depression Diet: salty, hot Lifestyle: tobacco, alcohol, NSAID Ehlers-Danlos type III

Reassure (must not belittle) Management of FD Diet: Visceral adiposity, canned food, alcohol weekly, high fat, salt, fermentable oli gosaccharides, disaccharides, monosaccharides, and polyols, carbonated drinks, h ot spices Antidepressants: TCA (not SSRI); amitriptyline 50 mg qd > escitalopram 10mg (ulcer-like epigastric pain & normal gastric emptying) Eradication of Helicobacter pylori: small population (10%) but significant Prokinetic agents: metoclopramide, domperidone, mosapride, cinitapride > domperidone in post-prandial fullness, early satiation, bloating itopride: meta-analysis, phase II, (not in phase III) acotiamide: phase II, large multicenter phase III in Japan (post-prandial distress, early satiation, bloating) Enhancing gastric accommodation: buspirone (post-prandial fullness, early satiation, bloating) Nonpharmacologic therapies: psychotherapy, acupuncture (high risk of bias) Herbal medicine: Iberogast (Germany), Rikkunshito (Japan), Menthacarin Novel approaches: cannabinoid-1 receptor, a novel target

Dyspepsia: a Clinical Guide

Conclusion Dyspepsia is difficult to define and manage